First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.

Debashis Sarker,Elizabeth R. Plummer,Bristi Basu,Tim Meyer,Kai-Wen Huang,T.R. Jeffry Evans,Duncan Spalding,Yuk Ting Ma,Daniel H. Palmer,Cheng Ean Chee,Han-Chong Toh,Nagy Habib

First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.

2017

Debashis Sarker
Elizabeth R. Plummer
Bristi Basu
Tim Meyer
Kai-Wen Huang
T.R. Jeffry Evans
Duncan Spalding
Yuk Ting Ma
Daniel H. Palmer
Cheng Ean Chee
Han-Chong Toh
Nagy Habib

TPS2612Background: saRNAs are small oligonucleotide drugs designed to selectively upregulate therapeutic proteins by recruiting endogenous transcriptional complexes to a target gene, leading to inc...

Keywords:

CEBPA
Transcription factor
Cancer research
Liver cancer
RNA
Pathology
Medicine
saRNA
Oligonucleotide
Downregulation and upregulation
Endogeny

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations